France's ABIONYX Pharma H1 net loss widens as financial expenses rise

Overview

• France biopharma's H1 2026 revenue declined, driven solely by IRIS Pharma CRO activities

• Net loss widened in H1 2026, mainly due to financial expenses from bond issuance

• Company ended H1 2026 with €26.9 mln in cash after recent financing transaction

Outlook

• Company expects IRIS Pharma revenue for 2026 to remain broadly stable vs 2025

• ABIONYX Pharma remains focused on GMP production for sepsis and LCAT deficiency

• Company preparing for next regulatory steps for Phase 2b sepsis trial

Result Drivers

• NO CORE REVENUE - Co's main business in sepsis and LCAT deficiency did not generate revenue in H1 2026; revenue came solely from IRIS Pharma's CRO activities

• HIGHER FINANCIAL EXPENSES - Net loss widened due to financial expenses from Fenja straight bonds issuance and fair-value measurement

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Abionyx Pharma SA is €10.00, about 440.5% above its September 23 closing price of €1.85

Reuters Recommended Reads

• Sept 21 - France's Abivax H1 net loss widens on higher expenses driven by clinical programs

• Sept 22 - European drugmakers call for faster trials, more spending to compete with US, China

• Sept 22 - Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)